Vivacelle Bio, Inc.

Biotechnology ResearchIllinois, United States11-50 Employees

VIVACELLE BIO, Inc. is a developmental stage biotechnology company  developing products utilizing nanoparticle technology.  Their first product, VBI-1, a colloid non-blood volume expander appears to be safer and far more effective than the standard treatment for hypovolemia in animal studies and received green light from FDA to start a phase IIa clinical trial in hypovolemia due to blood loss. The immediate other product in the pipeline is VBI-S, targeting hypovolemia due to sepsis/septic shock.  

Hypovolemia results from inadequate fluid volume in the blood vessels, causes the death of over a one million people globally each year.  Major causes for fluid loss are trauma, surgery, shock, sepsis, severe diarrhea and burns.  Inadequate circulating volume impairs tissue perfusion and oxygenation leading to cell injury and death. Rapid volume replacement and re-establishment of normal blood pressure are essential for survival. Currently  available options of fluid replacements are non-blood volume expanders (colloids and crystalloids), blood products and blood substitutes. They have proven to be impractical and have the potential for significant negative adverse effects. VBI-1,  represents a new paradigm in fluid resuscitation, safely restoring blood vessel volume and reversing the effects of hypovolemia.  VBI-1 also modulates Nitric Oxide (a potent vasodilator that drops the blood pressure and a precursor to highly highly toxic mediators), reduces reperfusion injury, 
inhibits the inflammatory response, clears the endotoxin, metabolizes to naturally-occurring components and acts as an energy source. In addition, it can be loaded with readily available oxygen.

Sign up for free to view info

Email Format Employee directory